---
reference_id: "PMID:19466295"
title: "Mismatch repair genes in Lynch syndrome: a review."
authors:
- Silva FC
- Valentin MD
- Ferreira Fde O
- Carraro DM
- Rossi BM
journal: Sao Paulo Med J
year: '2009'
doi: 10.1590/s1516-31802009000100010
content_type: abstract_only
---

# Mismatch repair genes in Lynch syndrome: a review.
**Authors:** Silva FC, Valentin MD, Ferreira Fde O, Carraro DM, Rossi BM
**Journal:** Sao Paulo Med J (2009)
**DOI:** [10.1590/s1516-31802009000100010](https://doi.org/10.1590/s1516-31802009000100010)

## Content

1. Sao Paulo Med J. 2009 Jan;127(1):46-51. doi: 10.1590/s1516-31802009000100010.

Mismatch repair genes in Lynch syndrome: a review.

Silva FC(1), Valentin MD, Ferreira Fde O, Carraro DM, Rossi BM.

Author information:
(1)Hospital AC Camargo, São Paulo, Brazil.

Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an 
autosomal-dominant inherited cancer predisposition syndrome caused by germline 
mutations in deoxyribonucleic acid (DNA) mismatch repair genes. Since the 
discovery of the major human genes with DNA mismatch repair function, mutations 
in five of them have been correlated with susceptibility to Lynch syndrome: mutS 
homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic 
segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1). 
It has been proposed that one additional mismatch repair gene, mutL homolog 3 
(MLH3), also plays a role in Lynch syndrome predisposition, but the clinical 
significance of mutations in this gene is less clear. According to the InSiGHT 
database (International Society for Gastrointestinal Hereditary Tumors), 
approximately 500 different LS-associated mismatch repair gene mutations are 
known, primarily involving MLH1 (50%) and MSH2 (40%), while others account for 
10%. Much progress has been made in understanding the molecular basis of Lynch 
Syndrome. Molecular characterization will be the most accurate way of defining 
Lynch syndrome and will provide predictive information of greater accuracy 
regarding the risks of colon and extracolonic cancer and enable optimal cancer 
surveillance regimens.

A síndrome de Lynch representa de 1-7% de todos os casos de câncer colorretal. É 
uma síndrome de herança autossômica dominante que predispõe ao câncer e é 
causada por mutações nos genes de reparo de ácido desoxirribonucléico (DNA). 
Desde a descoberta dos principais genes com função de reparo de DNA, mutações 
nos genes MSH2, MLH1, MSH6, PMS2 e PMS1 estão relacionadas com a 
susceptibilidade à síndrome de Lynch. Outro gene, MLH3, tem sido proposto como 
tendo papel na predisposição à síndrome de Lynch, porém mutações de 
significância clínica nesse gene não são claras. De acordo com o banco de dados 
InSiGHT (International Society for Gastrointestinal Hereditary Tumors), 
aproximadamente 500 diferentes mutações associadas à síndrome de Lynch são 
conhecidas, envolvendo primeiramente MLH1 (50%), MSH2 (40%) e outros (10%). 
Grandes progressos têm ocorrido para nosso entendimento das bases moleculares da 
síndrome de Lynch. A caracterização molecular será a forma mais precisa para 
definirmos a síndrome de Lynch e irá fornecer informações preditivas mais 
precisas sobre o risco de câncer colorretal e extra-colônico, além de permitir 
regimes otimizados de manejo.

DOI: 10.1590/s1516-31802009000100010
PMCID: PMC10969316
PMID: 19466295 [Indexed for MEDLINE]

Conflict of interest statement: Conflicts of interest: Not declared